202 related articles for article (PubMed ID: 28756084)
21. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
22. Management of multiple myeloma in older adults: Gaining ground with geriatric assessment.
Wildes TM; Campagnaro E
J Geriatr Oncol; 2017 Jan; 8(1):1-7. PubMed ID: 27118356
[TBL] [Abstract][Full Text] [Related]
23. Nuances in the Management of Older People With Multiple Myeloma.
Pawlyn C; Gay F; Larocca A; Roy V; Ailawadhi S
Curr Hematol Malig Rep; 2016 Jun; 11(3):241-51. PubMed ID: 27038805
[TBL] [Abstract][Full Text] [Related]
24. A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.
Rasche L; Menoret E; Dubljevic V; Menu E; Vanderkerken K; Lapa C; Steinbrunn T; Chatterjee M; Knop S; Düll J; Greenwood DL; Hensel F; Rosenwald A; Einsele H; Brändlein S
Clin Cancer Res; 2016 Sep; 22(17):4341-9. PubMed ID: 27029491
[TBL] [Abstract][Full Text] [Related]
25. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E; Redic K
J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
[TBL] [Abstract][Full Text] [Related]
26. Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Shah JJ
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():19-23. PubMed ID: 25184232
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
[TBL] [Abstract][Full Text] [Related]
28. Carfilzomib: a novel agent for multiple myeloma.
Redic K
J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
[TBL] [Abstract][Full Text] [Related]
29. Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Bringhen S; Gay F; Donato F; Troia R; Mina R; Palumbo A
Expert Opin Investig Drugs; 2014 Sep; 23(9):1193-209. PubMed ID: 24905450
[TBL] [Abstract][Full Text] [Related]
30. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
Danhof S; Schreder M; Rasche L; Strifler S; Einsele H; Knop S
Eur J Haematol; 2016 Jul; 97(1):25-32. PubMed ID: 26331915
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
[TBL] [Abstract][Full Text] [Related]
32. Ixazomib: First Global Approval.
Shirley M
Drugs; 2016 Mar; 76(3):405-11. PubMed ID: 26846321
[TBL] [Abstract][Full Text] [Related]
33. Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?
Klepin HD; Hurd DD
Bone Marrow Transplant; 2006 Nov; 38(9):585-92. PubMed ID: 16953209
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies.
Lim C; Sinha P; Harrison SJ; Quach H; Slavin MA; Teh BW
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):444-450.e3. PubMed ID: 33722538
[TBL] [Abstract][Full Text] [Related]
35. Proteasome inhibitors in the treatment of multiple myeloma.
McBride A; Ryan PY
Expert Rev Anticancer Ther; 2013 Mar; 13(3):339-58. PubMed ID: 23477520
[TBL] [Abstract][Full Text] [Related]
36. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
37. Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomib.
Siegel DS
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():2-3. PubMed ID: 25184229
[No Abstract] [Full Text] [Related]
38. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Harrison SJ; Mainwaring P; Price T; Millward MJ; Padrik P; Underhill CR; Cannell PK; Reich SD; Trikha M; Spencer A
Clin Cancer Res; 2016 Sep; 22(18):4559-66. PubMed ID: 27117181
[TBL] [Abstract][Full Text] [Related]
39. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Salvini M; Bonello F; Boccadoro M; Larocca A
Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
[TBL] [Abstract][Full Text] [Related]
40. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Bilotti E
Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
